Evidence map›Paper›PMID 41273515›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2026

Chiral High-Performance Liquid Chromatography (HPLC) in Targeted Metabolomics.

Xiaoqing Fu, Michael Lämmerhofer

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Xiaoqing FuPharmaceutical (Bio-)Analysis, Institute of Pharmaceutical Sciences, University of Tübingen, Tübingen, Germany.
Michael LämmerhoferPharmaceutical (Bio-)Analysis, Institute of Pharmaceutical Sciences, University of Tübingen, Tübingen, Germany. michael.laemmerhofer@uni-tuebingen.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Enzymatic reactions usually occur with a high substrate, product, or substrate-product stereoselectivity. In many instances, information on the stereochemical disposition of biologically active metabolites is indispensable for a complete understanding of biological processes and metabolic states. This raised interest in structural isomerism and stereoisomerism in metabolomics and lipidomics. While structural and geometrical isomers, as well as diastereomers, can be principally distinguished by achiral liquid chromatography (LC) and also ion-mobility mass spectrometry (MS), enantiomers require enantioselective separation methods. While untargeted enantioselective metabolomics is mostly based on the derivatization of metabolites with a chiral derivatizing agent, followed by LC separation on achiral columns and hyphenation with high-resolution mass spectrometry, targeted enantioselective LC with chiral stationary phases mostly employs robust triple quadrupole (QqQ) mass spectrometry for detection. It is a powerful technology, yet it focuses primarily on a broad, metabolite class-wide coverage. This chapter describes four distinct fields of application of targeted enantioselective LC-tandem mass spectrometry assays for important and representative metabolite classes. The first one deals with the enantioselective analysis of oxylipins using polysaccharide-based chiral columns, with protocols applicable for platelets and plasma; the second focuses on 3-hydroxy fatty acid enantiomer separations in plasma and platelets; the third application provides two workflows for proteinogenic enantioselective amino acid analysis; and the fourth application proposes methodologies for enantioselective short branched-chain fatty acid analysis. Critical aspects are discussed.

Indexed as

MetabolomicsAnimalsChromatography, High Pressure LiquidHumansStereoisomerismTandem Mass Spectrometry3-Hydroxy fatty acidAmino acidBranched alkanoic acidsChiral derivatizing agentChiral stationary phaseLC–MSLipidomicsMass spectrometryMetaboliteMetabolomicsOxylipin

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.